sab63090
9 minutes ago
Investor:
I was unable to read the continuation of the article since I am not a subscriber to STAT+, but the changes at the FDA are, for me, welcomed! Once safety issues have been provided, I am happy to see more flexibility and then to proceed to effectiveness.
I'm